Polaryx Therapeutics (PLYX) Liabilities and Shareholders Equity (2024 - 2026)
Polaryx Therapeutics (PLYX) posted quarterly Liabilities and Shareholders Equity of $3.5 million for Q1 2026, down 32.26% quarter-over-quarter from $5.2 million in Q4 2025.
Polaryx Therapeutics (PLYX) Liabilities and Shareholders Equity (2024 - 2026) Analysis & Trends
Polaryx Therapeutics (PLYX) has reported Liabilities and Shareholders Equity for 3 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $13.7 million (changed N/A YoY), while the FY2025 annual figure was $5.2 million, up 3.38% from the prior year.
- Liabilities and Shareholders Equity retreated to $3.5 million in Q1 2026 per PLYX's latest filing, from $5.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $5.2 million in Q4 2025 and bottomed at $3.5 million in Q1 2026.
- Historically, Liabilities and Shareholders Equity has averaged $4.6 million across 3 years, with a median of $5.0 million in 2024.
- On a YoY basis, Liabilities and Shareholders Equity climbed as much as 3.38% in 2025 and fell as far as 3.38% in 2025.
- Polaryx Therapeutics' Liabilities and Shareholders Equity stood at $5.0 million in 2024, then advanced by 3.38% to $5.2 million in 2025, then sank by 32.26% to $3.5 million in 2026.
- Business Quant data shows PLYX's Liabilities and Shareholders Equity at $3.5 million in Q1 2026, $5.2 million in Q4 2025, and $5.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Polaryx Therapeutics | 99.45 Mn | 87.91 Mn | - | 11.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.81 Mn |
| Mar 31, 2026 | 3.50 Mn |
| Dec 31, 2025 | 5.17 Mn |
| Dec 31, 2024 | 5.00 Mn |